Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Aug;5(4):E162-6.
doi: 10.3978/j.issn.2072-1439.2013.08.35.

Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review

Xu-Qin Jiang  1 , Lei Fang, Xiao-Dong Mei, Xiao-Jing Wang, Ming-Hong Bao
Affiliations
Case Reports

Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review

Xu-Qin Jiang et al. J Thorac Dis. 2013 Aug.

Abstract

Rituximab, a monoclonal antibody against CD20+ antigen specific B cell, has been increasingly used in the treatment of non-Hodgkin's lymphoma and some other autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. It is noted that Rituximab could enhanced the efficacy of CHOP-based chemotherapy. Meanwhile it could increase the opportunity of lung infection. Pneumocystis jiroveci pneumonia (PCP), a rare opportunistic infection that was not reported in the large-scale clinical trials of Rituximab, was found recently in patients with non-Hodgkin's lymphoma treated with remedy containing Rituximab. We herein report two cases of PCP in lymphoma patients after Rituximab-containing chemotherapy. Both patients were successfully treated, with trimethoprim-sulfamethoxazole (TMP-SMX) in one case and Caspofungin alone in the other. We also reviewed the literature and concluded that PCP is an infrequent but potentially life-threatening infection in patients with non-Hodgkin's lymphoma subjected to Rituximab-containing regimen. Therefore, adequate prophylaxis, timely diagnosis and treatment are necessary.

Keywords: Caspofungin; Rituximab; non-Hodgkin’s lymphoma; pneumocystis jiroveci pneumonia (PCP).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Thoracic computed tomography scanning revealed ground-glass opacities (GGO) in both upper lobes in Case 1 (A) and GGO vanished after treatment with SMZ/TMP (B). GGO were found in the right lung in Case 2 (C) and attenuated after treatment with Caspofungin alone (D).
See this image and copyright information in PMC

References

    1. Lund FE, Hollifield M, Schuer K, et al. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006;176:6147-54 - PubMed
    1. Hashimoto K, Kobayashi Y, Asakura Y, et al. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 2010;51:1816-21 - PubMed
    1. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener’s granulomatosis. Arthritis Care Res (Hoboken) 2010;62:1661-4 - PubMed
    1. Tsai MJ, Chou CW, Lin FC, et al. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus 2012;21:914-8 - PubMed
    1. Kato H, Yamamoto K, Taji H, et al. Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011;11:483-9 - PubMed

Publication types